XML 45 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Note 3 - Collaboration Revenue (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 31 Months Ended
Nov. 12, 2020
Nov. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Nov. 12, 2022
Revenue from Contract with Customer, Including Assessed Tax     $ 338 $ 0 $ 676 $ 0  
Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]              
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value     5,267   5,267    
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]              
Collaborative Arrangement, Upfront Cash Payment   $ 10,000          
Derivative Liability, Total     278   278    
Revenue from Contract with Customer, Including Assessed Tax     $ 338   $ 676    
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Convertible Preferred Shares [Member]              
Stock Issued for Transfer of Assets, Shares (in shares) 9,631,941            
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Preferred Shares [Member]              
Stock Issued During Period, Shares, New Issues (in shares) 1,194,030            
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-2 Preferred Shares [Member]              
Stock Issued During Period, Shares, New Issues (in shares) 1,990,000            
Shares Issued, Price Per Share (in dollars per share) $ 2.5125            
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Additional Series A-2 Preferred Shares [Member] | Forecast [Member]              
Stock Issued During Period, Shares, New Issues (in shares)             1,990,000
Shares Issued, Price Per Share (in dollars per share)             $ 2.5125
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Maximum [Member]              
Collaborative Arrangement, Equity Investment   $ 780,000